Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 11—November 2024
Synopsis

Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008–2019

Sarah Gorvetzian1, Antonio G. Pacheco, Erin Anderson, Susan M. Ray, and Marcos C. SchechterComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA (S. Gorvetzian, S.M. Ray, M.C. Schechter); Fundaçāo Oswaldo Cruz, Rio de Janeiro, Brazil (A.G. Pacheco); Georgia Department of Public Health, Atlanta (E. Anderson, S.M. Ray, M.C. Schechter)

Main Article

Table 3

Hazard ratios for TB cohort groups defined by univariate and multivariable models in study of mortality rates after TB treatment, Georgia, USA, 2008–2019*

Characteristics Univariate analysis, HR (95% CI) Multivariate model, HR (95% CI)†
Age, per year
 1.06 (1.05–1.07)
 1.06 (1.05–1.07)
Sex
F Referent NA
M
 1.23 (0.92–1.63)
 NA
US-born persons
 6.68 (4.60–9.70)
 3.42 (2.25–5.19)
Ethnicity‡
Non-Hispanic White Referent NA
Non-Hispanic Asian 0.23 (0.14–0.37) NA
Non-Hispanic Black 0.67 (0.49–0.91) NA
Hispanic, all races
 0.12 (0.06–0.23)
 NA
HIV status
Negative Referent Referent
Positive 1.70 (1.22–2.45) 1.87 (1.20–2.90)
Missing data
 1.72 (1.02–2.92)
 1.58 (0.90–2.78)
Injection drug use
No Referent NA
Yes 1.44 (0.55–4.00) NA
Missing data
 1.46 (0.36–5.91)
 NA
Excess alcohol use
No Referent Referent
Yes 2.38 (1.79–3.15) 1.64 (1.17–2.30)
Missing data
 1.30 (0.32–5.26)
 1.51 (0.34–6.75)
Homeless within past year
No Referent Referent
Yes 2.19 (1.58–3.04) 1.36 (0.89–2.08)
Missing data
 1.81 (0.25–12.90)
 17.3 (2.00–150.0)
Diabetes mellitus 2.83 (2.09–3.83) 2.05 (1.44–2.91)
End-stage renal disease
 3.36 (1.73–6.54)
 2.24 (1.05–4.80)
Case verification
Culture confirmed Referent NA
Clinical case 0.66 (0.47–0.93) NA
Other 1.12 (0.42–3.01) NA
Extrapulmonary 0.62 (0.43–0.91) NA
Cavitary disease, n = 2,511§
 1.14 (0.86–1.50)
 NA
Sputum smear, n = 2,511§
Negative Referent NA
Positive 1.00 (0.76–1.33) NA
Missing data
 0.82 (0.41–1.63)
 NA
Drug susceptibility, n = 2,318
RIF/INH susceptible Referent Referent
RIF susceptible/INH resistant 0.99 (0.62–1.57) 0.89 (0.55–1.49)
RIF resistant 0.49 (0.07–3.47) 0.89 (0.12–6.39)
Incomplete TB treatment 0.83 (0.49–1.40) NA

*HR, hazard ratio; INH, isoniazid; NA, not applicable; RIF, rifampin; TB, tuberculosis. †Model selected according to best fit of Akaike Information Criterion (21). ‡Other category was excluded because no deaths occurred in this group (n = 55). §Cavitary disease and sputum smear were not included in the multivariable models because the overall cohort included patients without pulmonary disease.

Main Article

References
  1. World Health Organization. Global tuberculosis report 2023 [cited 2024 Aug 1]. https://www.who.int/publications/i/item/9789240083851
  2. Byrne  AL, Marais  BJ, Mitnick  CD, Lecca  L, Marks  GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015;32:138–46. DOIPubMedGoogle Scholar
  3. Huaman  MA, Henson  D, Ticona  E, Sterling  TR, Garvy  BA. Tuberculosis and cardiovascular disease: linking the epidemics. Trop Dis Travel Med Vaccines. 2015;1:10. DOIPubMedGoogle Scholar
  4. Romanowski  K, Baumann  B, Basham  CA, Ahmad Khan  F, Fox  GJ, Johnston  JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:1129–37. DOIPubMedGoogle Scholar
  5. Menzies  NA, Quaife  M, Allwood  BW, Byrne  AL, Coussens  AK, Harries  AD, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021;9:e1679–87. DOIPubMedGoogle Scholar
  6. Basham  CA, Karim  ME, Cook  VJ, Patrick  DM, Johnston  JC. Post-tuberculosis mortality risk among immigrants to British Columbia, Canada, 1985-2015: a time-dependent Cox regression analysis of linked immigration, public health, and vital statistics data. Can J Public Health. 2021;112:132–41. DOIPubMedGoogle Scholar
  7. Uplekar  M, Weil  D, Lonnroth  K, Jaramillo  E, Lienhardt  C, Dias  HM, et al.; for WHO’s Global TB Programme. WHO’s new end TB strategy. Lancet. 2015;385:1799–801. DOIPubMedGoogle Scholar
  8. Dodd  PJ, Yuen  CM, Jayasooriya  SM, van der Zalm  MM, Seddon  JA. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021;21:984–92. DOIPubMedGoogle Scholar
  9. Miller  TL, Wilson  FA, Pang  JW, Beavers  S, Hoger  S, Sharnprapai  S, et al. Mortality hazard and survival after tuberculosis treatment. Am J Public Health. 2015;105:930–7. DOIPubMedGoogle Scholar
  10. Centers for Disease Control and Prevention, National Center for Health Statistics. National Death Index [cited 2024 Aug 1]. https://www.cdc.gov/nchs/ndi
  11. Georgia Department of Public Health. 2020 Georgia TB reference guide [cited 2024 Aug 1]. https://dph.georgia.gov/document/document/2020georgiatbreferenceguidepdf/download
  12. Nahid  P, Mase  SR, Migliori  GB, Sotgiu  G, Bothamley  GH, Brozek  JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e93–142. DOIPubMedGoogle Scholar
  13. Nahid  P, Dorman  SE, Alipanah  N, Barry  PM, Brozek  JL, Cattamanchi  A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63:e147–95. DOIPubMedGoogle Scholar
  14. Georgia Department of Public Health. State electronic notifiable disease surveillance system [cited 2024 Oct 4]. https://sendss.state.ga.us
  15. Georgia Department of Public Health. Online analytical statistical information system [cited 2024 Oct 4]. https://oasis.state.ga.us
  16. Georgia Department of Public Health. Diabetes [cited 2024 Jan 5]. https://dph.georgia.gov/chronic-disease-prevention/diabetes
  17. Centers for Disease Control and Prevention. BRFSS prevalence and trends data, alcohol consumption, heavy drinking, 2014 [cited 2023 Jan 5]. https://nccd.cdc.gov/BRFSSPrevalence/rdPage.aspx
  18. Georgia Department of Public Health. Georgia HIV surveillance data [cited 2024 Aug 2]. https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/georgia-hiv-surveillance-data
  19. US Department of Housing and Urban Development, Office of Policy Development and Research. 2014 AHAR: Part 1—PIT estimates of homelessness in the US [cited 2024 Aug 2]. https://www.huduser.gov/portal/datasets/ahar/2014-ahar-part-1-pit-estimates-of-homelessness.html
  20. World Population Review. Immigrants by state 2024 [cited 2024 Jan 5]. https://worldpopulationreview.com/state-rankings/immigrants-by-state
  21. Akaike  H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–23. DOIGoogle Scholar
  22. Klein  RJ, Schoenborn  CA. Centers for Disease Control and Prevention. Age adjustment using the 2000 projected U.S. population. Statistical notes, January 2001 [cited 2024 Oct 4]. https://www.cdc.gov/nchs/data/statnt/statnt20.pdf
  23. US Department of Commerce, Bureau of the Census. Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050 [cited 2024 Aug 1]. https://www.census.gov/content/dam/Census/library/publications/1996/demo/p25-1130.pdf
  24. von Elm  E, Altman  DG, Egger  M, Pocock  SJ, Gøtzsche  PC, Vandenbroucke  JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. DOIPubMedGoogle Scholar
  25. Park  SC, Kang  MJ, Han  CH, Lee  SM, Kim  CJ, Lee  JM, et al. Long-term mortality of patients with tuberculosis in Korea. Int J Tuberc Lung Dis. 2020;24:492–8. DOIPubMedGoogle Scholar
  26. Choi  H, Han  K, Jung  J-H, Park  SH, Kim  SH, Kang  HK, et al. Long-term mortality of tuberculosis survivors in Korea: a population-based longitudinal study. Clin Infect Dis. 2023;76:e973–81. DOIPubMedGoogle Scholar
  27. Joseph  Y, Yao  Z, Dua  A, Severe  P, Collins  SE, Bang  H, et al. Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti. J Int AIDS Soc. 2021;24:e25721. DOIPubMedGoogle Scholar
  28. Dangisso  MH, Woldesemayat  EM, Datiko  DG, Lindtjørn  B. Long-term outcome of smear-positive tuberculosis patients after initiation and completion of treatment: A ten-year retrospective cohort study. PLoS One. 2018;13:e0193396. DOIPubMedGoogle Scholar
  29. Liu  Y, Zheng  Y, Chen  J, Shi  Y, Shan  LY, Wang  S, et al. Tuberculosis-associated mortality and its risk factors in a district of Shanghai, China: a retrospective cohort study. Int J Tuberc Lung Dis. 2018;22:655–60. DOIPubMedGoogle Scholar
  30. Wang  X-H, Ma  A-G, Han  X-X, Liang  H, Wang  D, Schouten  E, et al. Survival and associated mortality risk factors among post-treatment pulmonary tubercolosis patients in the northwest of China. Eur Rev Med Pharmacol Sci. 2015;19:2016–25.PubMedGoogle Scholar
  31. Hendi  AS, Ho  JY. Immigration and improvements in American life expectancy. SSM Popul Health. 2021;15:100914. DOIPubMedGoogle Scholar
  32. Miller  EA, McCarty  FA, Parker  JD. Racial and ethnic differences in a linkage with the National Death Index. Ethn Dis. 2017;27:77–84. DOIPubMedGoogle Scholar
  33. Gray  NA, Boucher  NA, Cervantes  L, Berlinger  N, Smith  SK, Johnson  KS. Hospice access and scope of services for undocumented immigrants: a clinician survey. J Palliat Med. 2021;24:1167–73. DOIPubMedGoogle Scholar
  34. Lee-Rodriguez  C, Wada  PY, Hung  Y-Y, Skarbinski  J. Association of mortality and years of potential life lost with active tuberculosis in the United States. JAMA Netw Open. 2020;3:e2014481. DOIPubMedGoogle Scholar
  35. Schechter  MC, Bizune  D, Kagei  M, Holland  DP, Del Rio  C, Yamin  A, et al. Challenges across the HIV care continuum for patients with HIV/TB co-infection in Atlanta, GA. Open Forum Infect Dis. 2018;5:ofy063. DOIPubMedGoogle Scholar
  36. Johnston  JC, Cooper  R, Menzies  D. Chapter 5: treatment of tuberculosis disease. Can J Respir Crit Care Sleep Med. 2022;6(sup1):66–76. DOIGoogle Scholar
  37. Tsang  CA, Patel  NN, Stout  JE, Fernando  R, Pratt  R, Goswami  ND. Factors associated with receiving longer than recommended therapy among culture-negative pulmonary tuberculosis patients. Open Forum Infect Dis. 2022;9:ofac630. DOIPubMedGoogle Scholar

Main Article

1Current affiliation: University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Page created: September 12, 2024
Page updated: October 19, 2024
Page reviewed: October 19, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external